*Helicobacter pylori* is a common gastric pathogen that causes gastritis, peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. *H. pylori* infection has been linked to a number of rare gastric mucosal lesions with distinctive histological features, including rare forms of gastritis, such as lymphocytic gastritis (LG) \[[@b1-jptm-2017-04-03]-[@b5-jptm-2017-04-03]\] or granulomatous gastritis (GG) \[[@b3-jptm-2017-04-03],[@b4-jptm-2017-04-03],[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03]\], and abnormal immunoglobulin deposits, such as Russell body gastritis (RBG) \[[@b8-jptm-2017-04-03],[@b9-jptm-2017-04-03]\] or crystal-storing histiocytosis (CSH) \[[@b10-jptm-2017-04-03],[@b11-jptm-2017-04-03]\]. These lesions are easily diagnosed based on their distinctive histological features; however, their development can be attributed to various factors besides *H. pylori* infection. Therefore, the role of *H. pylori* as a causative organism remains debatable, and it has been suggested that *H. pylori* may be an "innocent bystander \[[@b2-jptm-2017-04-03],[@b4-jptm-2017-04-03],[@b12-jptm-2017-04-03]\]." Nevertheless, *H. pylori* eradication therapy has been linked to clinical and histological improvements in a subset of these lesions \[[@b7-jptm-2017-04-03],[@b13-jptm-2017-04-03]-[@b21-jptm-2017-04-03]\], which supports the role of *H. pylori* infection in their development and implies that *H. pylori* eradication therapy could be an effective treatment. Therefore, in this review, we investigate the relationship between these rare gastric lesions and *H. pylori* infection, describe their characteristic histological features, and evaluate the role of *H. pylori* infection in their pathogenesis.

RARE FORMS OF GASTRITIS
=======================

LG and GG are not distinct clinicopathological entities, but rather morphologic patterns of injury that can be secondary to a variety of underlying etiologies \[[@b2-jptm-2017-04-03]-[@b4-jptm-2017-04-03],[@b6-jptm-2017-04-03]\]. The histological identification of intraepithelial lymphocytosis and granuloma formation are key diagnostic features of LG and GG, respectively \[[@b1-jptm-2017-04-03]-[@b7-jptm-2017-04-03]\]. However, a morphological diagnosis of LG and GG should elicit clinical and laboratory workups to identify the underlying etiology. In Western countries, LG and GG are generally classified as special forms of *H. pylori*--negative gastritis \[[@b3-jptm-2017-04-03],[@b4-jptm-2017-04-03]\]. However, there is convincing evidence that *H. pylori* infection contributes to the pathogenesis of both LG \[[@b1-jptm-2017-04-03],[@b5-jptm-2017-04-03]\] and GG \[[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03],[@b22-jptm-2017-04-03]\], and that *H. pylori* eradication therapy may be an effective treatment \[[@b7-jptm-2017-04-03],[@b13-jptm-2017-04-03]-[@b15-jptm-2017-04-03],[@b17-jptm-2017-04-03],[@b23-jptm-2017-04-03],[@b24-jptm-2017-04-03]\]. Thus, it is possible that subsets of LG and GG could be categorized as *H. pylori*--associated gastritis. The potential role of *H. pylori* infection in the pathogenesis of each of these lesions is described below, along with their histopathological characteristics.

Lymphocytic gastritis
---------------------

LG, first described by Haot *et al.* \[[@b25-jptm-2017-04-03]\] in 1988, is a rare form of chronic gastritis that is characterized by a dense lymphocytic infiltration of the surface and pit gastric epithelium known as "intraepithelial lymphocytosis." LG was initially considered to be related to varioliform gastritis, which manifests as thickened mucosa with "octopus-sucker" targetoid erosions \[[@b25-jptm-2017-04-03],[@b26-jptm-2017-04-03]\]; however, the endoscopic features of LG vary according to its severity, ranging from normal to hypertrophic \[[@b2-jptm-2017-04-03],[@b27-jptm-2017-04-03]\]. Histologically, LG is defined by the presence of ≥25 intraepithelial lymphocytes (IELs) per 100 epithelial cells ([Fig. 1](#f1-jptm-2017-04-03){ref-type="fig"}). Gastric intraepithelial lymphocytosis is associated with a variety of conditions, including celiac disease, *H. pylori* infection, Crohn disease, syphilis, hypertrophic gastropathy, Ménétrier's disease, human immunodeficiency virus, and lymphoma \[[@b2-jptm-2017-04-03],[@b5-jptm-2017-04-03]\]. However, celiac disease and *H. pylori* infection are the main causes of LG, accounting for 38% and 29% of cases, respectively \[[@b5-jptm-2017-04-03],[@b13-jptm-2017-04-03],[@b28-jptm-2017-04-03]\]. The association between LG and celiac disease is relatively well established. Mild intraepithelial lymphocytosis with a low cut-off value (≥8 IELs/100 epithelial cells) has been observed in 84% of patients with celiac disease \[[@b29-jptm-2017-04-03]\], and LG occurs in up to 45% of patients, with resolution of LG in response to a gluten-free diet \[[@b5-jptm-2017-04-03],[@b13-jptm-2017-04-03],[@b28-jptm-2017-04-03]-[@b30-jptm-2017-04-03]\].

However, questions remain regarding the role of *H. pylori* infection in the development of LG due to the discrepancy between the prevalence of *H. pylori* in the general population and the incidence of LG among patients with *H. pylori*--associated gastritis \[[@b2-jptm-2017-04-03]-[@b4-jptm-2017-04-03]\]. Given the high global prevalence of *H. pylori* infection, it is unclear why the proportion of *H. pylori*--infected patients presenting with LG morphology (\<5%) is so low \[[@b5-jptm-2017-04-03]\]. Nevertheless, *H. pylori* eradication therapy can resolve *H. pylori*--associated LG by reducing IEL levels, and has been shown to improve symptoms and/or lead to regression of the gastritis \[[@b13-jptm-2017-04-03]-[@b16-jptm-2017-04-03]\], which supports a causal role of *H. pylori* infection in the development of LG. Previous studies have reported that *H. pylori*--associated LG frequently exhibits significant neutrophilic activity in addition to intraepithelial lymphocytosis \[[@b2-jptm-2017-04-03],[@b3-jptm-2017-04-03],[@b16-jptm-2017-04-03],[@b27-jptm-2017-04-03]\], which is distinct from celiac disease-associated LG that exhibits intraepithelial lymphocytosis without neutrophilic infiltration. In this context, Nielsen *et al.* \[[@b27-jptm-2017-04-03]\] argued that *H. pylori*--associated intraepithelial lymphocytosis accompanied with significant neutrophilic infiltration should be considered "chronic active gastritis," rather than LG. However, considering the fact that LG is a morphological diagnosis that is based on the presence of intraepithelial lymphocytosis (≥25 IELs per 100 epithelial cells), the use of the term "LG" remains relevant.

Interestingly, a considerable number of patients with LG and positive *H. pylori* serology did not exhibit histological evidence of *H. pylori* infection \[[@b1-jptm-2017-04-03],[@b14-jptm-2017-04-03],[@b15-jptm-2017-04-03],[@b27-jptm-2017-04-03]\]. In addition, the beneficial effects of *H. pylori* eradication therapy in LG have been observed in patients who had positive serology but negative histology for *H. pylori* \[[@b14-jptm-2017-04-03],[@b15-jptm-2017-04-03]\]. Furthermore, even when *H. pylori* infection has been histologically confirmed in patients with LG, colonization tends to be mild and focal \[[@b14-jptm-2017-04-03],[@b15-jptm-2017-04-03]\]. These results imply that failure to histologically detect *H. pylori* may be related to sampling error due to low-level infection \[[@b27-jptm-2017-04-03]\]. Also, it is possible that LG development is a local, transient, or delayed immunological reaction to *H. pylori* infection, and is not a direct effect of the infection \[[@b1-jptm-2017-04-03],[@b13-jptm-2017-04-03],[@b14-jptm-2017-04-03],[@b27-jptm-2017-04-03]\]. Thus, if other causes can be excluded, *H. pylori* eradication therapy could be considered in symptomatic patients with LG who are histologically and/or serologically positive for *H. pylori*. This approach may be more appropriate in countries with a low prevalence of celiac disease and a high prevalence of *H. pylori* infection, even without histological detection of *H. pylori*.

IELs are functionally and phenotypically distinct from peripheral lymphocytes, and the majority of IELs in the gastrointestinal epithelium are CD3^+^/CD8^+^ T cells with cytotoxic potential \[[@b31-jptm-2017-04-03]\]. These IELs are thought to play an important role in mucosal immunity and have also been implicated in epithelial cell turnover by eliciting apoptosis through cytotoxic T-lymphocytes (CTLs) \[[@b31-jptm-2017-04-03],[@b32-jptm-2017-04-03]\]. Recently, Han *et al.* \[[@b33-jptm-2017-04-03]\] studied IEL subpopulations and their cytotoxicity in *H. pylori*--infected gastric mucosa using T-cell--restricted intracellular antigen-1 (TIA-1; a marker for resting and activated CTLs) and granzyme B (GrB; a marker for activated CTLs). They found that the IELs consisted of a mixture of TIA-1^+^/GrB-- CTLs, TIA-1^+^/GrB^+^ CTLs, and CD4^+^ T cells in the infected mucosa. In addition, they found that *H. pylori*--associated LG was distinct from *H. pylori* gastritis, based on the increased IEL levels and changes in the cytotoxicity and distribution of the subpopulations: *H. pylori*--associated LG had a higher proportion of activated GrB^+^ CTLs, compared to *H. pylori* gastritis. There was also a parallel increase in epithelial apoptosis. Meanwhile, in a study by Oberhuber *et al.* \[[@b34-jptm-2017-04-03]\], the proportion of GrB^+^ CTLs in *H. pylori*--associated LG (10.8%) was lower than that in idiopathic LG (12%) or celiac disease--associated LG (18.9%). Thus, although LG exhibits consistent histological features (regardless of etiology), IEL characteristics may vary depending on the underlying condition, which can lead to different clinical manifestations.

Granulomatous gastritis
-----------------------

GG is a rare disease that is characterized by the presence of granulomas, and is detected in 0.01%--0.35% of gastric biopsies \[[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03],[@b17-jptm-2017-04-03],[@b35-jptm-2017-04-03]\]. GG can be caused by a number of factors, including systemic disease (e.g., Crohn disease, sarcoidosis, or vasculitis), infection (e.g., tuberculosis, histoplasmosis, or syphilis), underlying malignancy, or foreign bodies \[[@b4-jptm-2017-04-03],[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03],[@b36-jptm-2017-04-03]\]. Crohn's disease and gastric sarcoidosis are the two leading causes of GG, accounting for 20%--50% of cases in Western countries \[[@b6-jptm-2017-04-03],[@b35-jptm-2017-04-03]\]. Isolated or idiopathic granulomatous gastritis (IGG) was first described by Fahimi *et al.* \[[@b37-jptm-2017-04-03]\] in 1965, and is diagnosed by the exclusion of other granulomatous diseases. However, whether IGG can be considered a discrete condition remains controversial, as it is possible that a clear etiology could be identified through a more meticulous clinical work-up and long-term follow-up.

Dhillon and Sawyerr \[[@b22-jptm-2017-04-03]\] first reported an association between GG and *H. pylori* infection in 1989. Since then a number of reports have been published that support their findings \[[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03],[@b17-jptm-2017-04-03],[@b18-jptm-2017-04-03],[@b23-jptm-2017-04-03],[@b24-jptm-2017-04-03],[@b38-jptm-2017-04-03]-[@b42-jptm-2017-04-03]\]. These reports demonstrated that the mucosa surrounding granulomas in GG exhibits typical histological features of *H. pylori* gastritis, that features suggestive of other etiologies are absent, and that *H. pylori* eradication therapy can result in GG resolution. However, whether *H. pylori* plays a causative role in the pathogenesis of GG remains debatable. First, the incidence of GG is abnormally low relative to the *H. pylori* prevalence in the general population \[[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03],[@b12-jptm-2017-04-03],[@b35-jptm-2017-04-03]\]. Although Ectors *et al.* \[[@b6-jptm-2017-04-03]\] and Maeng *et al.* \[[@b7-jptm-2017-04-03]\] have reported the presence of *H. pylori* in 92% and 89% of GG cases, respectively, the overall incidences of GG were only 0.27% and 0.08%, respectively. Second, *H. pylori* organisms are rarely found within granulomas, implying *H. pylori* infection is a comorbidity rather than a cause in GG pathogenesis. Lastly, in cases of GG with *H. pylori* infection, granulomas often persist for 3--17 months after *H. pylori* eradication therapy \[[@b17-jptm-2017-04-03],[@b24-jptm-2017-04-03],[@b39-jptm-2017-04-03]\], making its efficacy in GG questionable. It is plausible that although *H. pylori* can cause GG, granuloma formation is the result of a rare host response as opposed to a direct effect. Thus, *H. pylori* eradication therapy would be less effective in the resolution of GG, compared to its efficacy in conventional *H. pylori* gastritis.

Histologically, *H. pylori*--associated GG exhibits small non-necrotizing epithelioid granulomas with Langhans giant cells ([Fig. 2](#f2-jptm-2017-04-03){ref-type="fig"}), which are similar to those that are associated with sarcoidosis or Crohn disease. These granulomas tend to form in distinctive locations, such as the foveolar isthmi \[[@b6-jptm-2017-04-03]\], with Maeng *et al.* \[[@b7-jptm-2017-04-03]\] reporting that the majority (66.7%) of granulomas were found there. They are also often in contact with a damaged pit (where *H. pylori* are commonly found) and are frequently accompanied by prominent neutrophilic infiltration, which distinguishes them from the granulomas that are observed in Crohn disease or sarcoidosis \[[@b6-jptm-2017-04-03],[@b7-jptm-2017-04-03]\]. However, this characteristic morphology and localization has not been consistently reported in subsequent studies \[[@b18-jptm-2017-04-03],[@b23-jptm-2017-04-03],[@b24-jptm-2017-04-03],[@b40-jptm-2017-04-03]-[@b42-jptm-2017-04-03]\]. Therefore, there are no distinct histologic features that could be used to confirm *H. pylori*--associated GG. Rather, it appears that the conditions in the mucosa surrounding granulomas are more informative \[[@b3-jptm-2017-04-03],[@b4-jptm-2017-04-03],[@b7-jptm-2017-04-03]\], as the presence of *H. pylori* and neutrophil-rich chronic active gastritis (associated with glandular atrophy or intestinal metaplasia) increase the likelihood of *H. pylori* infection. Taken together, although the presence of *H. pylori* in the vicinity of granulomas does not imply a causative association, *H. pylori* eradication therapy should be considered when there are no other underlying disease except *H. pylori* infection.

INTRACELLULAR IMMUNOGLOBULIN ACCUMULATION IN ASSOCIATION WITH HELICOBACTER PYLORI INFECTION
===========================================================================================

Immunoglobulin accumulations can be found in reactive and neoplastic plasma cells and include large intracytoplasmic spherical inclusions (Russell bodies), small intracytoplasmic morular inclusions (Mott cells), intranuclear inclusions (Dutcher bodies), and rare angular- or needle-shaped intracytoplasmic crystalline inclusions. These accumulations are associated with chronic inflammation with plasmacytosis, autoimmune disease, multiple myeloma, or other B-cell lymphomas \[[@b43-jptm-2017-04-03]-[@b45-jptm-2017-04-03]\]. Although the exact mechanism of immunoglobulin accumulation is unclear, it may be due to simple over-production, altered production, abnormal secretion, or impaired excretion \[[@b46-jptm-2017-04-03],[@b47-jptm-2017-04-03]\]. In the gastric mucosa, diffuse plasma cell infiltration with immunoglobulin overproduction may result from chronic over-stimulation of plasma cells by mucosal pathogens, especially *H. pylori*. Scattered Russell bodies are often observed with *H. pylori* gastritis, whereas Dutcher bodies are frequently associated with low-grade MALT lymphoma. However, RBG and CSH are rarely reported in the stomach \[[@b9-jptm-2017-04-03],[@b10-jptm-2017-04-03]\]. As the incidence of these lesions is low relative to *H. pylori*--associated gastritis, the contribution of *H. pylori* infection to their development is questionable. Furthermore, careful evaluation of their underlying cause is essential, as they can be associated with monoclonal gammopathy or lymphoreticular neoplasms \[[@b20-jptm-2017-04-03],[@b43-jptm-2017-04-03],[@b48-jptm-2017-04-03]\]. The possible connections between *H. pylori* infection and these immunoglobulin accumulations, diagnostically relevant histological features, and biological significance are described below.

Russell body gastritis
----------------------

The first case of RBG was reported by Tazawa and Tsutsumi in 1998 \[[@b19-jptm-2017-04-03]\]. RBG is a rare form of chronic gastritis characterized by localized accumulation of Mott cells, which are plasma cells with a cytoplasm packed with small spherical inclusions ([Fig. 3A](#f3-jptm-2017-04-03){ref-type="fig"}, [B](#f3-jptm-2017-04-03){ref-type="fig"}). These lesions are rare, and only 30 cases of RBG have been published to date in the English literature \[[@b8-jptm-2017-04-03],[@b9-jptm-2017-04-03],[@b19-jptm-2017-04-03]-[@b21-jptm-2017-04-03],[@b48-jptm-2017-04-03]-[@b61-jptm-2017-04-03]\]. The clinical and pathological features of RBG are summarized in [Table 1](#t1-jptm-2017-04-03){ref-type="table"}. Although its pathogenesis has not been fully elucidated, there is evidence to support a strong association between *H. pylori* infection and RBG development. For example, *H. pylori* is detected in approximately two-thirds of patients with RBG \[[@b8-jptm-2017-04-03],[@b9-jptm-2017-04-03],[@b19-jptm-2017-04-03]-[@b21-jptm-2017-04-03],[@b48-jptm-2017-04-03],[@b50-jptm-2017-04-03],[@b52-jptm-2017-04-03],[@b53-jptm-2017-04-03],[@b55-jptm-2017-04-03],[@b57-jptm-2017-04-03],[@b60-jptm-2017-04-03],[@b61-jptm-2017-04-03]\]. Few other infections that have been reported with RBG include human immunodeficiency virus (three patients) \[[@b51-jptm-2017-04-03],[@b53-jptm-2017-04-03],[@b59-jptm-2017-04-03]\], hepatitis C virus (one patient) \[[@b58-jptm-2017-04-03]\], and candida esophagitis (one case) \[[@b49-jptm-2017-04-03]\]. In addition, more than 60% of patients with RBG exhibit lesion regression following *H. pylori* eradication therapy \[[@b19-jptm-2017-04-03]-[@b21-jptm-2017-04-03],[@b53-jptm-2017-04-03],[@b60-jptm-2017-04-03]\]. Furthermore, it has been reported that highly virulent *H. pylori* genotypes (vacA and cagA) are associated with the formation of Russell bodies and Mott cells in the antral mucosa \[[@b62-jptm-2017-04-03]\].

Immunoglobulin light chain restriction is generally considered to be proof of monoclonality and is an important indicator of B-cell neoplasia. Interestingly, light chain restriction was detected via immunohistochemistry in 12 out of 30 cases of RBG (kappa restriction in 11 cases and lambda restriction in one case) \[[@b9-jptm-2017-04-03],[@b20-jptm-2017-04-03],[@b48-jptm-2017-04-03],[@b58-jptm-2017-04-03],[@b61-jptm-2017-04-03]\]. Ten of these cases were localized gastric lesions with no associated lymphoid malignancy or plasma cell disorder, although one case was associated with low-grade MALT lymphoma \[[@b48-jptm-2017-04-03]\], and another with concomitant monoclonal gammopathy of undetermined significance \[[@b20-jptm-2017-04-03]\]. This could be explained by the findings of Girón and Shah \[[@b63-jptm-2017-04-03]\], who reported that approximately 50% of patients with *H. pylori* infection exhibit either kappa or lambda light chain elevation, and suggested that *H. pylori* infection might contribute to immunoglobulin light chain dysfunction. Thus, RBG may be closely associated with *H. pylori* infection, and the majority of RBG cases may be reactive in nature, even when light chain monoclonality is detected. Nevertheless, pathologists should be aware of the possibility of concomitant lymphoid neoplasms.

Given the strong association with *H. pylori* infection, it is possible that RBG, gastric carcinoma, or MALT lymphoma might occur simultaneously in the same patient. Previous reports describe Mott cell proliferation (features of RBG) in association with gastric carcinoma, including two cases of Epstein-Barr virus--positive lymphoepithelioma-like carcinoma \[[@b55-jptm-2017-04-03]\], and one case of signet ring cell carcinoma \[[@b57-jptm-2017-04-03]\]. In these cases, Mott cell proliferation was likely a reactive paraneoplastic event, given that the carcinoma and Mott cells did not mix and that the Mott cells were polyclonal. However, in the previously described case of RBG with concomitant MALT lymphoma \[[@b48-jptm-2017-04-03]\], the Mott cells were mixed with the neoplastic centrocyte-like cells ([Fig. 3C](#f3-jptm-2017-04-03){ref-type="fig"}) and exhibited IgM kappa monoclonality, which indicates the proliferating Mott cells were neoplastic components of MALT lymphoma.

Morphologically, Mott cells with eccentric nuclei and abundant eosinophilic cytoplasm are similar to poorly differentiated carcinoma cells or signet ring cells. In addition, in cases with abundant Mott cells and a few neoplastic cells, neoplastic cells may not be easily detected. Thus, immunostaining for cytokeratin should be conducted to exclude associated carcinoma \[[@b55-jptm-2017-04-03],[@b57-jptm-2017-04-03]\]. Furthermore, if light chain monoclonality is detected, pathologists should consider associated MALT lymphoma and perform ancillary immunostaining (e.g., for CD20 and cytokeratin) to identify centrocytelike cells and lymphoepithelial lesions ([Fig. 3D](#f3-jptm-2017-04-03){ref-type="fig"}) \[[@b48-jptm-2017-04-03]\].

Crystal-storing histiocytosis
-----------------------------

CSH is a rare condition, which often occurs with disorders such as monoclonal gammopathy, B-cell lymphoma, or plasma cell myeloma \[[@b43-jptm-2017-04-03],[@b64-jptm-2017-04-03],[@b65-jptm-2017-04-03]\]. Although many cases of CSH are systemic, organ-confined CSH has been described in the lung, lymph node, kidney, thyroid, thymus, parotid gland, and cornea \[[@b43-jptm-2017-04-03],[@b65-jptm-2017-04-03]-[@b71-jptm-2017-04-03]\]. CSH is extremely rare in the stomach, and only eight cases of gastric CSH have been described to date in the English literature ([Table 2](#t2-jptm-2017-04-03){ref-type="table"}) \[[@b10-jptm-2017-04-03],[@b11-jptm-2017-04-03],[@b43-jptm-2017-04-03],[@b71-jptm-2017-04-03],[@b72-jptm-2017-04-03]\]. Among these, *H. pylori* infection was identified in four patients (50%) who did not exhibit concomitant gastric lesions (except for *H. pylori* gastritis) or a systemic disorder that might have caused monoclonal gammopathy \[[@b10-jptm-2017-04-03],[@b11-jptm-2017-04-03]\]. In the other four patients, there was no mention of *H. pylori* infection \[[@b43-jptm-2017-04-03],[@b71-jptm-2017-04-03],[@b72-jptm-2017-04-03]\], and two of them were subsequently diagnosed with thymic lymphoma \[[@b43-jptm-2017-04-03]\] and plasma cell myeloma \[[@b71-jptm-2017-04-03]\], respectively. Therefore, although overproduction of immunoglobulin due to *H. pylori* infection could be a plausible cause of isolated gastric CSH, clinical workup is needed to exclude the possibility that it is a manifestation of underlying lymphoma or plasma cell myeloma. Light chain restriction was detected in five of seven cases (kappa restriction in two case and lambda restriction in three cases) \[[@b10-jptm-2017-04-03],[@b71-jptm-2017-04-03],[@b72-jptm-2017-04-03]\], all of which except one had no associated B-cell/plasmacytic neoplasms. Thus, light chain restriction detected in isolated gastric CSH does not necessarily mean that it is associated with B-cell or plasmacytic neoplasm. Meanwhile, because no studies have reported CSH responding to *H. pylori* eradication therapy, its effectiveness is unclear.

Histologically, CSH is characterized by diffuse infiltrations of large, oval, polygonal, and, occasionally, spindle cells, with abundant eosinophilic cytoplasm and small eccentric nuclei. The eosinophilic cytoplasm is filled with elongated, rectangular, and needle-shaped/fibrillary crystalline inclusions ([Fig. 4](#f4-jptm-2017-04-03){ref-type="fig"}). These crystalline inclusions are approximately 5--20 nm long and are frequently arranged in parallel arrays \[[@b11-jptm-2017-04-03],[@b43-jptm-2017-04-03],[@b66-jptm-2017-04-03]\]. At low magnification, nodular aggregates of these cells can sometimes resemble adult rhabdomyomas or granular cell tumors in the way that they expand or displace normal structures, and proliferations of benign-looking histiocyte-like cells can also resemble Gaucher disease or malakoplakia \[[@b43-jptm-2017-04-03],[@b65-jptm-2017-04-03],[@b73-jptm-2017-04-03],[@b74-jptm-2017-04-03]\]. Therefore, immunostaining for desmin, smooth muscle actin, S100 protein, and immunoglobulin light chains can facilitate an accurate diagnosis \[[@b11-jptm-2017-04-03],[@b43-jptm-2017-04-03],[@b65-jptm-2017-04-03],[@b66-jptm-2017-04-03],[@b74-jptm-2017-04-03]\].

CONCLUSION
==========

This review examined several rare gastric lesions that have distinctive histological characteristics and are associated with a variety of conditions, including *H. pylori* infection. Although *H. pylori* may be a cause in many of these conditions, the association cannot be viewed as definite, given the low incidence of these lesions relative to the high prevalence of *H. pylori* infection, regional differences in the prevalence of *H. pylori* infection, and the possibility of other causative disorders. However, it is reasonable to consider *H. pylori* once other potential etiologies have been excluded. In addition, it is not advisable to consider *H. pylori* to be an "innocent bystander," given the considerable proportion of these lesions that can be regressed or cured with *H. pylori* eradication therapy. Therefore, it is important that pathologists properly identify a lesion's cause in order to ensure appropriate patient management. In this context, *H. pylori* should be considered as a possible cause in areas where it is prevalent. Further investigation is needed to confirm the role of *H. pylori* in the development of rare gastric lesions.
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![Lymphocytic gastritis. (A) The biopsy specimen shows a marked increase in intraepithelial lymphocytes (IELs) (over 25 IELs per 100 epithelial cells) with a top-heavy distribution. (B) Most IELs are positive for CD3 immunostaining.](jptm-2017-04-03f1){#f1-jptm-2017-04-03}

![Granulomatous gastritis. (A) The biopsy specimen demonstrates diffuse chronic active gastritis with confluent granulomas including multinucleated giant cells. (B) A well-defined granuloma is noted just below the surface foveolar epithelium. Some Helicobacter pylori organisms are seen (arrows).](jptm-2017-04-03f2){#f2-jptm-2017-04-03}

![Russell body gastritis with concomitant mucosa-associated lymphoid tissue lymphoma. (A) Mott cells are plasma cells in which the cytoplasm is packed with multiple variable-sized Russell bodies. (B) The lamina propria of the gastric mucosa is expanded by extensive infiltration of Mott cells, consistent with Russell body gastritis. (C) Small- to intermediate-sized atypical lymphoid cells, morphologically consistent with centrocyte-like cells are admixed with Mott cells and destroy adjacent gastric glands to form a lymphoepithelial lesion (circle). (D) Immunostaining for cytokeratin highlights a lymphoepithelial lesion.](jptm-2017-04-03f3){#f3-jptm-2017-04-03}

![Gastric crystal-storing histiocytosis. (A) The biopsy specimen demonstrates many large pinkish mononuclear cells in the lamina propria. (B) Higher magnification of mononuclear cells shows densely eosinophilic, refractile, needle-shaped, intracytoplasmic crystalline inclusions.](jptm-2017-04-03f4){#f4-jptm-2017-04-03}

###### 

Clinical and pathologic findings of previously published cases of Russell body gastritis in the English literature

  Case   Study                                               Age (yr)/Sex   Endoscopic finding                    *Helicobacter pylori* infection   Ig light chain of Mott cells   Gastric lesion coexisted     HPET/Resolution of RBG   Others
  ------ --------------------------------------------------- -------------- ------------------------------------- --------------------------------- ------------------------------ ---------------------------- ------------------------ -----------------------
  1      Tazawa and Tsutsumi \[[@b19-jptm-2017-04-03]\]      53/M           Multiple ulcer scars                  Yes                               Polyclonal                     None                         Done/Yes                 \-
  2      Erbersdobler *et al.* \[[@b49-jptm-2017-04-03]\]    80/F           Irregular mucosal swelling            No                                Polyclonal                     None                         NS                       *Candida* esophagitis
  3      Ensari *et al.* \[[@b50-jptm-2017-04-03]\]          70/M           Flattened gastric folds               Yes                               Polyclonal                     None                         Done/NS                  \-
  4      Paik *et al.* \[[@b8-jptm-2017-04-03]\]             47/F           Erythematous swelling                 Yes                               Polyclonal                     None                         Done/NS                  \-
  5      Paik *et al.* \[[@b8-jptm-2017-04-03]\]             53/F           Yellowish raised lesion               Yes                               Polyclonal                     None                         Done/NS                  \-
  6      Wolkersdörfer *et al.* \[[@b20-jptm-2017-04-03]\]   54/M           Erythema and erosions                 Yes                               Monoclonal (λ)                 None                         Done/Yes                 MGUS
  7      Drut and Olenchuk \[[@b51-jptm-2017-04-03]\]        34/M           Elevation with central macule         No                                Polyclonal                     None                         NS                       HIV infection
  8      Pizzolitto *et al.* \[[@b52-jptm-2017-04-03]\]      60/F           Minute-raised granular areas          Yes                               Polyclonal                     None                         Done/NS                  \-
  9      Licci *et al.* \[[@b53-jptm-2017-04-03]\]           59/M           Hyperemia                             Yes                               Polyclonal                     None                         Done/Yes                 HIV infection
  10     Habib *et al.* \[[@b54-jptm-2017-04-03]\]           75/M           Nodular chronic active gastritis      No                                Polyclonal                     None                         NS                       \-
  11     Shinozaki *et al.* \[[@b55-jptm-2017-04-03]\]       74/M           Centrally ulcerated bulky mass        Yes                               Polyclonal                     EBV-positive carcinoma       No                       \-
  12     Shinozaki *et al.* \[[@b55-jptm-2017-04-03]\]       29/F           Ulcerated mass                        Yes                               Polyclonal                     EBV-positive carcinoma       No                       \-
  13     Del Gobbo *et al.* \[[@b56-jptm-2017-04-03]\]       78/F           Hyperemic gastric mucosa              No                                Polyclonal                     None                         No                       \-
  14     Wolf *et al.* \[[@b57-jptm-2017-04-03]\]            67/M           Exophytic tumor                       Yes                               NS                             Signet ring cell carcinoma   No                       \-
  15     Coryne and Azadeh \[[@b58-jptm-2017-04-03]\]        49/M           Severe raised erosive gastritis       No                                Monoclonal (κ)                 None                         NS                       HCV infection
  16     Bhalla *et al.* \[[@b59-jptm-2017-04-03]\]          82/M           Gastritis                             No                                Polyclonal                     None                         NS                       HIV infection
  17     Karabagli and Gokturk \[[@b60-jptm-2017-04-03]\]    60/M           Large ulcerofungating mass            Yes                               Polyclonal                     None                         Done/Yes                 \-
  18     Yoon *et al.* \[[@b21-jptm-2017-04-03]\]            57/M           Elevation with central depression     Yes                               Polyclonal                     None                         Done/Yes                 \-
  19     Yoon *et al.* \[[@b21-jptm-2017-04-03]\]            43/M           Whitish flat lesion with nodularity   Yes                               Polyclonal                     None                         Done/Yes                 \-
  20     Araki *et al.* \[[@b61-jptm-2017-04-03]\]           74/F           Ulcer                                 Yes                               Monoclonal (κ)                 None                         No                       \-
  21     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            78/F           Gastritis with uneven mucosa          No                                Monoclonal (κ)                 None                         No                       \-
  22     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            77/F           Gastritis with uneven mucosa          Yes                               Monoclonal (κ)                 None                         No                       \-
  23     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            77/F           Punctiform erosion                    Yes                               Monoclonal (κ)                 None                         No                       \-
  24     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            56/M           Raised erosion                        Yes                               Monoclonal (κ)                 None                         No                       \-
  25     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            76/M           Erythema                              Yes                               Monoclonal (κ)                 None                         No                       \-
  26     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            50/M           Flat and raised erosions              Yes                               Monoclonal (κ)                 None                         No                       \-
  27     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            28/M           Erythema                              No                                Monoclonal (κ)                 None                         No                       \-
  28     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            24/F           Erythema                              No                                Monoclonal (κ)                 None                         No                       \-
  29     Zhang *et al.* \[[@b9-jptm-2017-04-03]\]            66/M           Ulceration                            No                                NA                             None                         No                       \-
  30     Joo \[[@b48-jptm-2017-04-03]\]                      56/M           Hyperemia and micronodularity         Yes                               Monoclonal (κ)                 MALT lymphoma                No                       \-

HPET, *Helicobacter pylori* eradication therapy; RBG, Russell body gastritis; M, male; F, female; NS, not stated; MGUS, monoclonal gammopathy of undetermined significance; HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; HCV, hepatitis C virus; NA, not assessed; MALT, mucosa-associated lymphoid tissue.

###### 

Clinical and pathologic findings of six cases of gastric crystal-storing histiocytosis

  Case No.   Study                                             Age (yr)/Sex   Endoscopic finding   Ig light chains     Crystal-ctoring cells          Helicobacter pylori infection
  ---------- ------------------------------------------------- -------------- -------------------- ------------------- ------------------------------ -------------------------------
  1          Jones *et al.* \[[@b43-jptm-2017-04-03]\]         35/F           NS                   Polyclonal          Histiocytes                    NS
  2          Stewart and Spagnolo \[[@b10-jptm-2017-04-03]\]   82/M           Gastritis            Monoclonal (IgAλ)   Plasma cells                   Positive
  3          Stewart and Spagnolo \[[@b10-jptm-2017-04-03]\]   81/M           Gastritis            NA                  Plasma cells                   Positive
  4          Stewart and Spagnolo \[[@b10-jptm-2017-04-03]\]   52/F           Gastritis            Monoclonal (IgAλ)   Plasma cells                   Positive
  5          Joo *et al.* \[[@b11-jptm-2017-04-03]\]           56/F           Polyps (three)       Polyclonal          Plasma cells and histiocytes   Positive
  6          Vaid *et al.* \[[@b72-jptm-2017-04-03]\]          NS             Submucosal tumor     Monoclonal (κ)      Histiocytes                    NS

F, female; NS, not stated; M, male; NA, not assessed.
